INHIBIKASE THERAPEUTICS INC. - COMMON STOCK

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

07 Feb 2024 07:55:00 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

29 Jan 2024 09:05:00 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

16 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

19 Dec 2023 08:30:00 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

04 Dec 2023 08:35:00 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

14 Nov 2023 16:30:06 By Nasdaq GlobeNewswire

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

07 Nov 2023 09:28:32 By Nasdaq GlobeNewswire

Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023

07 Nov 2023 08:00:01 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment

16 Oct 2023 07:00:27 By Nasdaq GlobeNewswire

Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

04 Oct 2023 08:30:00 By Nasdaq GlobeNewswire